Quick Overview

The colorectal cancer report part comprises defined and up to date development strategies for 347 colorectal cancer drugs within the portfolio of 182 investigators, from Ceased to Marketed. This part extensively analyses their 210 identified drug targets, organized into 205 drug target strategies, and assesses them in eight different compound strategies in colorectal cancer.

Request Sample Pages or Access via 1stOncology™

You can request Free Sample Pages to A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market.

To find out more about A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market, please read the product description below.We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

Did you know that A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market is part of the 1stOncology™ platform and can be accessed at no extra cost?

1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.

This report comprises defined and up to date development strategies for 347 colorectal cancer drugs within the portfolio of 182 companies, from Ceased to Marketed. The report extensively analyses their 210 identified drug targets, organized into 205 drug target strategies, and assesses them in eight different compound strategies in colorectal cancer. BioSeeker has applied its unique drug assessment methodology to stratify the colorectal cancer pipeline and discern the level of competition in fine detail.Major Findings from this report:

* The identified competitive landscape of colorectal cancer drugs is split between the 45% which have unique drug target strategies and the other part which have head-to-head target competing colorectal cancer drugs in 49 different clusters. The latter has a competing ratio which is more than two times higher than the comparable average of the colorectal cancer drugs in general. Contributing to this fact is heavily utilized drug target strategies like: TOP1, TYMS, CEACAM5, EGFR and TUBB.

* Nine out of ten drug target strategies in Phase II development are new to colorectal cancer drugs and at the same time the greatest numbers of new target strategies are found in Phase II (37%) and Phase I development (21%).

* Small molecules, antibodies and proteins are the dominating compound strategies of colorectal cancer drugs, which represent four fifths of the entire pipeline. Cell therapy based colorectal cancer drugs has the lowest representation of defined target strategy portfolio compared to that of other compound strategies of colorectal cancer drugs.

* The highest number of described drug target strategies of colorectal cancer drugs belongs to Pfizer, Novartis, Hoffmann-La Roche, Eli Lilly and Amgen.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any colorectal cancer drug to ensure that the optimal market conditions exist by the time the product is commercialized.

Request Sample Pages or Access via 1stOncology™

You can request Free Sample Pages to A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market.To find out more about A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market, please read the product description below.We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

Did you know that A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market is part of the 1stOncology™ platform and can be accessed at no extra cost?

1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.

This report is an important part of creating and implementing a market development plan for any protein kinase drug in oncology to ensure that the optimal market conditions exist by the time the product is commercialized.Learn More